EPCAM_HUMAN TACSTD1 ELISA tesk kit
- Known as:
- EPCAM_HUMAN TACSTD1 Enzyme-linked immunosorbent assay test tesk reagent
- Catalog number:
- gen16484
- Product Quantity:
- 1
- Category:
- Peptides
- Supplier:
- Other suppliers
- Gene target:
- EPCAM_HUMAN TACSTD1 ELISA tesk kit
Related genes to: EPCAM_HUMAN TACSTD1 ELISA tesk kit
- Gene:
- EPCAM NIH gene
- Name:
- epithelial cell adhesion molecule
- Previous symbol:
- M4S1, MIC18, TACSTD1
- Synonyms:
- Ly74, TROP1, GA733-2, EGP34, EGP40, EGP-2, KSA, CD326, Ep-CAM, HEA125, KS1/4, MK-1, MH99, MOC31, 323/A3, 17-1A, TACST-1, CO-17A, ESA
- Chromosome:
- 2p21
- Locus Type:
- gene with protein product
- Date approved:
- 1995-10-02
- Date modifiied:
- 2019-04-23
Related products to: EPCAM_HUMAN TACSTD1 ELISA tesk kit
Related articles to: EPCAM_HUMAN TACSTD1 ELISA tesk kit
- Programmed death-ligand 1 (PD-L1) blockade improves outcomes in patients with various malignancies; however, biomarkers for monitoring treatment responses are lacking. This study presents a surface-enhanced Raman scattering (SERS)-based platform for the ultrasensitive detection of PD-L1 on circulating epithelial cell adhesion molecule-positive (EpCAM) extracellular vesicles (EVs). The platform is validated using interferon-gamma-treated epithelial tumor cell line-derived EVs. The platform is further applied to paired pre- and post-treatment plasma samples from patients with non-small-cell lung cancer (n = 140) and head and neck squamous cell carcinoma (n = 73) receiving anti-PD-(L)1 immunotherapy. Dynamic changes in PD-L1 expression on EV are shown to correlate with clinical outcomes. A post-treatment decrease in PD-L1 expression on EpCAM EVs (EpCAM EV PD-L1) is associated with improved 5-year progression-free and overall survival. These results establish EpCAM EV PD-L1 as a dynamic, non-invasive biomarker for monitoring immunotherapy responses and demonstrate the utility of SERS-based profiling in predicting long-term responses to immune checkpoint blockade. - Source: PubMed
Publication date: 2026/07/03
Mun ByeonggeolKim JinyoungKim Chang GonGo SeokhyeongHan MinaOuck YujinJang SoojinSon Seong UkKim GaminSon WonrakKim EunjungHong Min HeeYeo Ja HyunLim Eun-KyungKim Hye RyunHaam Seungjoo - The optimal first-line pharmacological therapy for newly diagnosed type 2 diabetes mellitus (T2DM) remains uncertain. This trial compared the vascular and molecular effects of dapagliflozin monotherapy, metformin monotherapy, and their combination in this population. - Source: PubMed
Publication date: 2026/07/03
Chee Ying JieAcharyya SanchalikaLiew HuilingSeow Cherng JyeGoh Liuh LingBoehm Bernhard ODalan Rinkoo - Chronic obstructive pulmonary disease (COPD) is a common progressive respiratory disease with persistent airflow limitation, chronic airway inflammation, and limited early diagnostic biomarkers and targeted therapies. MicroRNAs (miRNAs) are involved in COPD pathogenesis, but the role of microRNA-129-5p (miR-129-5p) in COPD is unclear. This study investigated miR-129-5p's association with COPD susceptibility, its regulation on cigarette smoke extract (CSE)-induced bronchial epithelial cell injury, and the mechanism involving intercellular cell adhesion molecule 1 (ICAM1) and RELA. - Source: PubMed
Publication date: 2026/06/30
Liu DanWang JingfanZhang PingQin YonggangPan Yunchang - Integrin alpha X (ITGAX, CD11c) functions as a leukocyte adhesion molecule vital for immune cell activation, antigen presentation, and inflammatory responses. However, the expression profile, clinical relevance, immunoregulatory functions, and underlying mechanisms of ITGAX in clear cell renal cell carcinoma (ccRCC) remain incompletely elucidated. - Source: PubMed
Publication date: 2026/07/02
Chen XuehuaLin ZongrongZhang RanranXie HaominKong WeiyiFu ZhenyangPei Xiaojuan - Cadherin-17 (CDH17) is a cell-adhesion molecule physiologically expressed along the intestinal epithelial tight junctions. Aberrant overexpression of CDH17 in gastrointestinal (GI) cancers promotes tumor growth and metastasis and is associated with poor patient prognosis. Due to its restricted expression in normal tissues and strong association with malignancy, CDH17 represents an emerging therapeutic target for GI tract cancers. - Source: PubMed
Publication date: 2026/03/12
Yu MingcanMu GuangmaoChen PengBi HongleiZhou FulaiZha ZhengxiaHuang ShengJiang HaoJin YingChen YuantingChiu Mark LZhang Di